PROCEPT BioRobotics Corporation PRCT
- Market cap
- $1.0B
- P/E
- 0.0×
Follow PRCT
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | — | — | — | 24.20 | 15.38 | 24.83 | 39.48 | 27.80 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| — | — | — | — | — | 47.73 | 52.40 | 43.90 | 103.81 | 89.49 |
High Price
|
|||
| — | — | — | — | 205 | 234 | 428 | 626 | 756 | 888 |
Employees
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | 6 | 8 | 34 | 75 | 136 | 224 | 308 |
Revenue
|
|||
| — | — | — | (30.56%) | (16.26%) | 46.02% | 49.44% | 52.17% | 61.07% | 63.70% |
Gross Margin
|
|||
| — | — | — | (42) | (53) | (60) | (87) | (106) | (91) | (95) |
EBT
|
|||
| — | — | — | (680.42%) | (687.04%) | (173.62%) | (116.18%) | (77.70%) | (40.55%) | (30.96%) |
EBT Margin
|
|||
| — | 0 | — | (42) | (53) | (60) | (87) | (106) | (91) | (96) |
Net Income
|
|||
| — | — | — | 1 | 3 | 3 | 3 | 4 | 5 | 6 |
Depreciation
|
|||
| — | — | — | 0.14 | 2.11 | 2.09 | 1.69 | 2.88 | 4.31 | 5.55 |
Revenue/Sh
|
|||
| — | — | — | (0.97) | (14.47) | (3.63) | (1.96) | (2.24) | (1.75) | (1.72) |
Earnings/Sh
|
|||
| — | — | — | (1.01) | (13.20) | (3.48) | (1.81) | (2.29) | (1.90) | (0.88) |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (0.06) | (0.04) | (0.06) | (0.53) | (0.08) | (0.17) |
Capex/Sh
|
|||
| — | — | — | (1.01) | (13.26) | (3.51) | (1.87) | (2.82) | (1.99) | (1.05) |
Free CF/Sh
|
|||
| — | — | — | 0.68 | 16.64 | 16.21 | 4.44 | 5.94 | 7.72 | 6.59 |
Book Value/Sh
|
|||
| — | — | — | 43 | 4 | 16 | 44 | 47 | 52 | 56 |
Shares
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
PE Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 11.96 | 23.42 | 14.38 | 18.70 | 5.67 |
PS Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 1.54 | 8.91 | 6.98 | 10.43 | 4.78 |
PB Ratio
|
|||
| — | — | — | 0.00 | 0.00 | 4.68 | 21.18 | 12.88 | 17.45 | 4.92 |
EV/Sales
|
|||
| — | — | — | (1.69) | (1.69) | (2.79) | (19.14) | (13.17) | (37.80) | (25.96) |
EV/FCF
|
|||
| — | — | — | (44) | (48) | (57) | (80) | (108) | (99) | (49) |
Op' Cash Flow
|
|||
| — | — | — | (8) | 0 | (1) | (3) | (25) | (4) | (9) |
Capex
|
|||
| — | — | — | (44) | (49) | (58) | (83) | (133) | (104) | (58) |
FCF
|
|||
| — | — | — | 44 | 96 | 310 | 237 | 305 | 429 | 385 |
Working Cap'
|
|||
| — | — | — | 23 | 52 | 54 | 55 | 53 | 53 | 52 |
Total Debt
|
|||
| — | — | — | (19) | (48) | (251) | (168) | (204) | (280) | (235) |
Net Debt
|
|||
| — | — | — | 29 | 61 | 267 | 197 | 281 | 402 | 366 |
Sh' Equity
|
|||
| — | — | — | (135.41%) | (56.41%) | (25.85%) | (26.97%) | (29.66%) | (19.48%) | (18.34%) |
ROA
|
|||
| — | — | — | 0.00% | (225.01%) | (206.72%) | (170.70%) | (88.89%) | (49.51%) | (49.56%) |
ROIC
|
|||
| — | — | — | 25.69% | 32.45% | (142.17%) | (37.55%) | (44.32%) | (26.77%) | (24.89%) |
ROE
|
|||
PROCEPT BioRobotics Corporation peers in Medical Devices
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ENOV Enovis Corporation | $1.1B | 0.0× | Compare |
| TNDM Tandem Diabetes Care, Inc. | $1.1B | 0.0× | Compare |
| LMRI Lumexa Imaging Holdings, Inc. | $949.2M | 0.0× | Compare |
| IRMD iRadimed Corporation | $1.1B | 47.1× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| CBLL CeriBell, Inc. | $914.2M | 0.0× | Compare |
| AORT Artivion, Inc. | $1.1B | 0.0× | Compare |
| BVS Bioventus Inc. | $1.1B | 17.0× | Compare |
| BBNX Beta Bionics, Inc. | $1.2B | 0.0× | Compare |
PROCEPT BioRobotics Corporation (PRCT) key facts
- PROCEPT BioRobotics Corporation (PRCT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
- PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.
- PROCEPT BioRobotics Corporation reported a net loss of $95.6 million, or a loss of $1.72 per share, for fiscal 2025.
- As of September 25, 2026, PRCT traded at $17.20, a market capitalization of $1.0 billion.
- Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 2.9× sales.
- Return on equity was −24.9% and debt-to-equity 0.15.
PROCEPT BioRobotics Corporation (PRCT) Latest News
11 Aug
PROCEPT BioRobotics (PRCT) released its Q2 2026 earnings call transcript covering financial results and outlook. Quarterly earnings updates typically drive short-term stock moves but rarely alter long-term company trajectory.
8 Aug
Analysts cut growth forecasts for PROCEPT BioRobotics (PRCT), triggering a drop in the stock's assessed fair value. Reduced analyst growth estimates lower fair value targets and can weigh on near-term investor sentiment and share price.
5 Aug
PROCEPT BioRobotics reports strong HYDROS demand in Q2 2026 earnings call highlights, supporting revenue growth and operational momentum. Strong HYDROS demand signals major revenue upside and improved competitive positioning for PROCEPT BioRobotics.
PROCEPT BioRobotics Corporation held its Q2 2026 earnings call covering financial results and company updates. Q2 earnings data and guidance can moderately shift investor views on near-term performance.
4 Aug
PROCEPT BioRobotics Q2 earnings call highlights include revenue results, procedural growth in robotic urology systems, margin trends, and updated full-year guidance. Quarterly earnings and guidance updates typically produce moderate short-term stock moves without altering long-term fundamentals.
PROCEPT BioRobotics Corporation reported its second quarter 2026 financial results. Quarterly earnings releases supply performance data that can shift near-term investor views and valuation.
29 Jul
PROCEPT BioRobotics faces lawsuits over handpiece discounting that could undermine its positive investment case and affect future performance. Handpiece discounting lawsuits introduce legal risks that may affect PROCEPT BioRobotics' pricing, financial results and market position.
29 Jun
Evercore initiates coverage on PROCEPT BioRobotics (PRCT) with an Outperform rating citing Aquablation growth potential. Positive analyst initiation citing Aquablation growth potential can moderately lift PRCT investor sentiment and near-term trading.
31 May
PROCEPT BioRobotics shares fell 9.2% following Aquablation WATER IV milestones. Aquablation milestones signal clinical progress that can shift short-term sentiment and adoption outlook without fundamentally redefining company trajectory.
28 May
PROCEPT BioRobotics completed enrollment in the WATER IV Study for its prostate cancer program and secured expanded IDE approval to advance clinical development. WATER IV enrollment completion plus expanded IDE approval advances regulatory and commercialization pathway for core prostate treatment technology.
14 May
American Urological Association strengthens guideline recommendation for Aquablation therapy in BPH treatment, positioning PROCEPT BioRobotics' image-guided robotic system as a preferred option alongside laser enucleation. AUA guideline upgrade elevates Aquablation to top-tier status, driving clinical adoption, procedure growth, and PRCT revenue potential.
12 May
Procept Biorobotics Corp (PRCT) Q1 results reveal critical insights into its stock outlook, highlighting performance metrics and future trajectory implications. Q1 results represent major financial data directly shaping PRCT's investor sentiment and market performance.
4 May
PROCEPT BioRobotics (PRCT) missed Q4 expectations and reset guidance lower, prompting a shift in its investment story amid concerns over procedure growth slowdown and margin pressures. Q4 earnings miss and lowered guidance directly threaten PRCT's growth trajectory and investor confidence.
1 May
PROCEPT BioRobotics (PRCT) strengthens growth narrative after Aquablation system upgrade and HYDROS launch, enhancing competitive positioning and future prospects. Aquablation upgrade and HYDROS launch drive significant product innovation and market expansion for PRCT.
30 Apr
PROCEPT BioRobotics (PRCT) released Q1 2026 earnings call transcript covering financial results, operational updates, and forward guidance. Q1 earnings transcript details financial performance and strategic outlook, likely driving significant shifts in investor sentiment and stock trajectory.
PROCEPT BioRobotics Corporation released Q1 2026 earnings call summary, detailing financial results, procedure growth, AquaBeam system adoption, revenue projections, and updated full-year guidance. Q1 earnings highlights signal strong procedural growth and raised guidance, poised to boost investor confidence and stock performance.
PROCEPT BioRobotics (PRCT) delivered strong revenue growth in Q1 2026 earnings call, despite ongoing challenges. Strong revenue growth in Q1 2026 earnings highlights significant positive momentum for PRCT's financial trajectory and investor confidence.
29 Apr
PROCEPT BioRobotics reported Q1 revenue of $41.4 million, up 144% year-over-year, driven by 91% procedure growth and installed base expansion to 655 AquaBeam systems. Gross margins improved to 73.5%, operating loss narrowed, and full-year revenue guidance raised to $170-178 million amid strong U.S. adoption and international expansion. Robust revenue beat, procedure growth, margin expansion, and raised guidance position PRCT for accelerated market penetration and improved financial trajectory.
PROCEPT BioRobotics Corporation (PRCT) reported first quarter 2026 financial results, highlighting key revenue growth, procedure volume increases, and operational updates. Q1 2026 financial results disclosure directly influences PRCT's revenue trajectory, profitability, and investor sentiment.
PROCEPT BioRobotics Corporation (PRCT) reported a Q1 net loss but exceeded revenue estimates. Revenue beat despite Q1 loss highlights strong top-line growth offsetting investment-driven bottom-line pressure.
14 Apr
PROCEPT BioRobotics (PRCT) released its earnings call transcript detailing quarterly financial results, Aquablation system performance, procedure growth, revenue guidance, and management outlook. Earnings transcripts disclose financial metrics, growth updates, and future guidance that significantly impact investor sentiment and stock trajectory.
27 Mar
EAU guideline upgrade elevates Aquablation therapy to a prominent recommendation for BPH treatment, spotlighting PROCEPT BioRobotics Corporation (PRCT) and its Omni platform. EAU upgrade strengthens Aquablation's clinical endorsement, poised to accelerate PRCT adoption, revenue growth, and investor confidence.
26 Mar
PROCEPT BioRobotics (PRCT) strengthens its investment case with an expanding installed base of systems. Expanding system base drives recurring revenue growth and improves long-term market performance for PRCT.
23 Mar
EAU Guidelines upgrade Aquablation Therapy to strong surgical recommendation for BPH treatment, enhancing PROCEPT BioRobotics Corporation (PRCT) market position and adoption potential. EAU guidelines upgrade to strong recommendation fundamentally boosts Aquablation adoption, PRCT revenue, and competitive dominance in BPH therapy.
12 Mar
PROCEPT BioRobotics Corporation announces the international launch of the HYDROS Robotic System, expanding global access to AI-enabled Aquablation therapy. International rollout of advanced AI-enabled robotic system drives significant revenue potential and market expansion.
3 Mar
Truist Securities lowered its price target for PROCEPT BioRobotics Corporation (PRCT) from $47 to $30. Truist's significant price target cut from $47 to $30 for PRCT indicates moderated growth expectations, likely influencing market sentiment and stock performance moderately.
1 Mar
PROCEPT BioRobotics unveiled 2026 growth targets, higher average selling prices, and a profitability roadmap at Investor Day. 2026 growth targets, higher ASPs, and profitability roadmap outline major strategic shifts enhancing PRCT's trajectory and investor outlook.
28 Feb
PROCEPT BioRobotics (PRCT) missed Q4 revenue expectations and issued a softer 2026 outlook, prompting a reevaluation of its valuation amid concerns over growth trajectory. Q4 revenue miss and weaker 2026 guidance directly threaten financial performance and investor sentiment, potentially altering the company's market trajectory.
26 Feb
PROCEPT BioRobotics Corporation (PRCT) shares plummet following a hard-to-stomach update. Stock plummet on disappointing update signals significant negative impact on PRCT's market performance and trajectory.
PROCEPT BioRobotics Corporation released Q4 2025 earnings call summary detailing financial results, operational updates, and future outlook. Q4 earnings call summaries reveal critical financial performance and guidance that significantly shape investor expectations and stock trajectory.